This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XBI
Immunovant (IMVT) Up on Positive Initial IMVT-1402 MAD Study Data
by Zacks Equity Research
Immunovant (IMVT) posts encouraging initial results from the 600 mg MAD cohort of its early-stage study on IMVT-1402. Stock rises.
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
by Zacks Equity Research
Sector ETF report for XBI
Immunovant (IMVT) Q2 Earnings Top Estimates, Pipeline in Focus
by Zacks Equity Research
Immunovant (IMVT) reports better-than-expected fiscal second-quarter 2023 results. Pipeline development is on track, with several data readouts scheduled from both batoclimab and IMVT-1402 programs.
Biotech Stock Roundup: ICPT Up on Buyout Deal, IMVT & PLRX Gain on Study Data
by Zacks Equity Research
Acquisition news from Intercept (ICPT) and study updates from Immunovant (IMVT) are in focus in the biotech sector.
Immunovant (IMVT) Soars on Upbeat Initial IMVT-1402 Study Data
by Zacks Equity Research
Immunovant (IMVT) announces encouraging initial results from its early-stage study of IMVT-1402. The stock of the company rallies 97%.
Immunovant (IMVT) Q1 Loss Wider Y/Y, Pipeline in Focus
by Zacks Equity Research
Immunovant's (IMVT) reports wider-than-expected loss for fiscal first-quarter 2023. IMVT is on track with the pipeline developments.
Immunovant, Inc. (IMVT) Down 10.6% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Immunovant, Inc. (IMVT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is IQ Chaikin U.S. Small Cap ETF (CSML) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for CSML
Immunovant (IMVT) Q4 Earnings Top Estimates, Pipeline in Focus
by Zacks Equity Research
Immunovant (IMVT) reports narrower-than-expected results in fourth-quarter fiscal 2023. Pipeline development is on track. Stock surges 12% on Monday.
Is IQ Chaikin U.S. Small Cap ETF (CSML) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for CSML
Should IQ Chaikin U.S. Small Cap ETF (CSML) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for CSML
Is IQ Chaikin U.S. Small Cap ETF (CSML) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for CSML
Should IQ Chaikin U.S. Small Cap ETF (CSML) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for CSML
The Zacks Analyst Blog Highlights Merck, Vertex Pharmaceuticals, Immunocore Holdings and Immunovant
by Zacks Equity Research
Merck, Vertex Pharmaceuticals, Immunocore Holdings and Immunovant are part of the Zacks top Analyst Blog.
4 Drug Stocks Up More Than 40% YTD With Room to Grow in 2023
by Kinjel Shah
Here are four drug companies, MRK, VRTX, IMCR and IMVT, that are up 40% or more in 2022 so far and still have room for growth in 2023.
Are Medical Stocks Lagging Immunovant (IMVT) This Year?
by Zacks Equity Research
Here is how Immunovant, Inc. (IMVT) and McKesson (MCK) have performed compared to their sector so far this year.
Are Medical Stocks Lagging BioVie (BIVI) This Year?
by Zacks Equity Research
Here is how BioVie Inc. (BIVI) and Immunovant, Inc. (IMVT) have performed compared to their sector so far this year.
Reasons to Add Immunovant (IMVT) Stock to Your Portfolio Now
by Zacks Equity Research
Immunovant (IMVT) is progressing well with its lead pipeline candidate batoclimab being developed for treating myasthenia gravis, thyroid eye disease and other autoimmune diseases.
Immunovant (IMVT) Rises More Than 150% in 3 Months: Here's How
by Zacks Equity Research
Immunovant (IMVT) is making good progress with its lead pipeline candidate, batoclimab, which is being developed for treating myasthenia gravis, thyroid eye disease and other autoimmune diseases.
Is BioVie (BIVI) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how BioVie Inc. (BIVI) and Immunovant, Inc. (IMVT) have performed compared to their sector so far this year.
Immunovant's (IMVT) Q2 Earnings In Line, Batoclimab in Focus
by Zacks Equity Research
Immunovant's (IMVT) earnings meet estimates in the fiscal second quarter ending Sep 30, 2022. IMVT deepens focus on developing its lead candidate batoclimab.
Immunovant (IMVT) Set to Develop Lead Candidate Batoclimab
by Zacks Equity Research
Immunovant (IMVT) expects its lead pipeline candidate, batoclimab, being developed for treating several types of autoimmune diseases, to capture good market share, owing to its differentiated profile.
Immunovant (IMVT) Up More Than 20% in Past 3 Months: Here's Why
by Zacks Equity Research
Immunovant's (IMVT) lead pipeline candidate, batoclimab, is being developed for treating myasthenia gravis, thyroid eye disease and other autoimmune diseases.
Immunovant, Inc. (IMVT) Upgraded to Buy: Here's Why
by Zacks Equity Research
Immunovant, Inc. (IMVT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.